The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England

► We investigated the cost-effectiveness of replacing PCV-7 with PCV-13. ► We used the outcome of a dynamic infectious disease model. ► We used vaccine-type specific disease outcomes obtained from a hospital dataset. ► The cost-effectiveness of PCV-13 is borderline cost effective. ► The outcome depends on a number of assumptions for which evidence is limited.